Breaking Down CKD Corporation Financial Health: Key Insights for Investors

Curious whether CKD Corporation (6407.T) is a resilient buy or a value trap? With fiscal-year revenue of ¥155.63 billion (up 15.78% YoY) and TTM revenue at ¥152.52 billion (+6.16% YoY) but a recent quarter dip of 3.42% to ¥36.40 billion, the top line paints a nuanced picture; profitability metrics - including a gross margin of 28.4%, net margin of 8.7% and operating margin of 11.62% - helped drive net income of ¥12.94 billion (up 36% YoY) alongside a healthy ¥13.47 billion in free cash flow, while balance-sheet strength shows a 64.7% equity ratio, low debt-to-equity of 0.26 and a net cash position of ¥3.71 billion keeping solvency metrics robust (current ratio 3.61, Altman Z-Score 3.56); valuation multiples (P/E 14.83, EV/EBITDA 7.04, P/B 1.25) and an intrinsic value estimate of ¥2,774.44 versus market ¥2,748.00 suggest marginal undervaluation even as semiconductor demand headwinds and revised FY2026 forecasts pose risks - read on for a line-by-line breakdown of revenue drivers, margins, cash flow dynamics, leverage, valuation and where CKD's R&D and patent portfolio could unlock the next growth phase.

CKD Corporation (6407.T) - Revenue Analysis

CKD Corporation reported solid top-line expansion for FY ending March 31, 2025, though the most recent quarter showed a modest pullback. Key revenue metrics and context are summarized below.

• FY Mar 31, 2025 revenue: ¥155.63 billion (up 15.78% YoY).
• Trailing twelve months (TTM) revenue: ¥152.52 billion (up 6.16% YoY).
• Quarter ended Sep 30, 2025 revenue: ¥36.40 billion (down 3.42% YoY).
• Revenue per employee: ~¥32.86 million (4,641 employees).
• Market capitalization: ¥184.89 billion; Price-to-Sales (P/S): 1.21.

Interpretation highlights:

• The FY and TTM growth rates indicate an overall positive revenue trajectory, supported by a double-digit annual increase in FY2025 despite more moderate TTM gains.
• The quarter-to-quarter decline (-3.42% in Sep 2025) suggests cyclicality or near-term headwinds; however, the larger annual gain (15.78%) points to recovery or one-off strengths earlier in the fiscal year.
• Revenue per employee (~¥32.86M) provides a useful productivity benchmark when comparing peers in industrial automation and components manufacturing.
• P/S of 1.21 with a market cap of ¥184.89B positions the stock in a valuation band that warrants comparison against sector averages to assess relative expensiveness.

For deeper ownership and investor behavior context, see: Exploring CKD Corporation Investor Profile: Who's Buying and Why?

CKD Corporation (6407.T) - Profitability Metrics

• Gross profit margin (FY ending Mar 31, 2025): 28.4%
• Net profit margin (FY ending Mar 31, 2025): 8.7%
• Operating margin (period reported): 11.62%
• EBITDA margin (period reported): 16.04%
• Return on equity (ROE): 9.21%
• Net income (FY ending Mar 31, 2025): ¥12.94 billion (↑36% YoY)
• Free cash flow: ¥13.47 billion (positive)

• Cost structure: Effective management produced an operating margin of 11.62% and an EBITDA margin of 16.04%, signaling disciplined OPEX and favorable gross-to-operating conversion.
• Profitability despite revenue pressure: Operating and ordinary profits expanded >14% in the six-month window even as net sales fell 4.1%, implying margin recovery from either pricing, lower input costs, or mix shift.
• Strong cash generation: Positive free cash flow of ¥13.47 billion supports capital expenditure, debt servicing and potential shareholder returns.
• Shareholder returns efficiency: ROE at 9.21% combined with net income growth of 36% (¥12.94 billion) reflects improving bottom-line performance relative to equity.

CKD Corporation (6407.T) - Debt vs. Equity Structure

• Equity ratio: 64.7% - a majority of assets are financed by shareholders' equity.
• Debt-to-equity ratio: 0.26 - low leverage relative to equity.
• Total debt: ¥34.32 billion; total liabilities: ¥73.28 billion.
• Total assets: ¥210.26 billion; stockholders' equity: ¥136.98 billion.
• Cash and cash equivalents: ¥35.35 billion; net cash position: ¥3.71 billion.

• Implication: With an equity ratio of 64.7% and a debt-to-equity of 0.26, CKD maintains low financial risk and flexibility for capital allocation or M&A.
• Liquidity: ¥35.35 billion in cash provides near-term stability and supports working capital needs.
• Net cash: Positive net cash of ¥3.71 billion reduces refinancing risk and interest exposure.

CKD Corporation (6407.T) - Liquidity and Solvency

• Current ratio: 3.61 - ample short-term assets relative to short-term liabilities, reducing liquidity strain in business cycles.
• Quick ratio: 2.20 - solid ability to cover immediate obligations without relying on inventory conversion.
• Interest coverage ratio: 33.50 - operating earnings cover interest expense by a wide margin, indicating very low rollover/default risk on debt service.

• Cash generation: An operating cash flow to net income ratio of 1.42 indicates CKD turns reported earnings into cash efficiently - a positive sign for covering dividends, working capital needs, and discretionary spend.
• Capex impact: Free cash flow to net income at 0.99 shows capital expenditures consume very little of earnings, leaving substantial cash available for strategic uses.
• Balance-sheet resilience: Combined high current and quick ratios alongside an Altman Z-Score of 3.56 suggest low solvency risk and comfortable margin for lenders and creditors.

CKD Corporation (6407.T) - Valuation Analysis

• Current market price: ¥2,748.00
• Estimated intrinsic value: ¥2,774.44 - implying a small margin of safety and slight undervaluation relative to market price

• Relative valuation context: A P/E ~14.8 and EV/EBITDA ~7.0 position CKD Corporation (6407.T) in a value-friendly zone versus many industrial peers, indicating modest earnings multiple and attractive enterprise-level valuation.
• Cash generation metrics: P/FCF of 10.55 and P/OCF of 8.90 show the market is pricing the company at roughly 8-11 years of current cash-flow generation, a reasonable multiple for a capital-equipment supplier with stable orders.
• Balance-sheet capitalization: P/B 1.25 and P/TBV 1.26 indicate limited premium over book and tangible equity, suggesting conservative market expectations for asset revaluation or growth.

• Enterprise-value implications: EV ¥185.58 billion with EV/EBITDA 7.04 signals potential upside for acquirers or investors seeking cash-flow-backed valuation rather than pure earnings multiples.
• Valuation gap: Intrinsic value ¥2,774.44 vs market ¥2,748.00 - a narrow gap that could tighten or reverse with minor changes in earnings, cash flow, or discount-rate assumptions.

CKD Corporation (6407.T) - Risk Factors

CKD Corporation (6407.T) faces several material risks that investors should weigh against its otherwise solid balance-sheet metrics (Piotroski F-Score 8) and moderate volatility (beta 0.96). Below are the principal risk drivers and related quantified impacts reflected in the company's revised FY ending March 31, 2026 forecasts.

• Slow recovery in semiconductor-related components demand, pressuring revenue and margins.
• Revised FY Mar-31-2026 financial forecasts that reflect weaker end-market demand.
• Dividend adjustments and a payout policy that distributes a meaningful portion of earnings (payout ratio 42.50%).
• Market/industry cyclicality: exposure to automation and semiconductor supply-chain swings.
• Currency and raw material cost volatility affecting translated results and margins.

Key takeaways for risk monitoring:

• Revenue sensitivity: a 10-15% shortfall in semiconductor-related orders translates to double-digit cuts in consolidated sales and disproportionate operating margin erosion due to fixed costs.
• Dividend sustainability: with a 42.5% payout ratio, dividends remain supported at current earnings levels, but a deeper earnings decline could force policy revisions.
• Volatility and downside: beta 0.96 implies share moves will roughly track the market; sector shocks (semiconductor cycle) pose asymmetric downside risk.
• Balance-sheet resilience: Piotroski F-Score of 8 signals strong fundamentals, which helps absorb cyclical swings but does not eliminate near-term profit pressure.

For broader context on CKD Corporation's business model and historical positioning within its markets, see: CKD Corporation: History, Ownership, Mission, How It Works & Makes Money

CKD Corporation (6407.T) - Growth Opportunities

CKD Corporation (6407.T) is positioning for multi-dimensional growth by leveraging R&D, proprietary technologies, geographic expansion, and strong cash generation to capitalize on recovering industrial end-markets.

• R&D investment focus: Management continues to allocate resources to research and development to maintain technological leadership in factory automation, fluid control and motion-control systems. This sustained R&D emphasis supports new product cycles and higher-margin solutions.
• Proprietary technologies and patents: CKD's robust portfolio of proprietary technologies and patents underpins defensible product differentiation across pneumatic components, electric actuators and custom automation modules.
• International expansion: The company is targeting growth outside Japan through expanded sales channels, localized production and strategic partnerships to capture demand in ASEAN, North America and Europe.
• Semiconductor-related opportunity: With semiconductor equipment and assembly demand showing signs of recovery, CKD's components used in precision automation and fluid control are positioned to benefit as capital spending in the sector resumes.
• Strategic investments and M&A optionality: Strong operating cash generation provides capacity for bolt-on acquisitions, JV investments or capacity expansion to accelerate entry into adjacent markets.

Key strategic levers for investors to watch:

• R&D output: new product introductions and patent filings that convert into upstream pricing power.
• Conversion of free cash flow (¥13.47 billion) into capex, targeted M&A or shareholder returns.
• Revenue exposure to semiconductor capital spending and timing of cyclical recovery.
• Execution on international expansion - sales growth and margin sustainability outside Japan.

For more detail on investor composition and ownership trends, see: Exploring CKD Corporation Investor Profile: Who's Buying and Why?